The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A high proportion of tumors arise due to mutation of the p53 tumor suppressor protein. A p53 hotspot mutation at amino acid position 273 from R to H, flanking a peptide epitope that spans residues 264–272, renders cells resistant to killing by human histocompatibility leukocyte antigen (HLA)-A*0201–restricted cytotoxic T lymphocytes (CTLs) specific for this epitope. Acquisition of the R to H mutation at residue 273 of the human p53 protein promotes tumor growth in vivo by selective escape from recognition by p53.264–272 peptide-specific CTLs. Synthetic 27-mer p53 polypeptides covering the antigenic nonamer region 264–272 of p53 were used as proteasome substrates to investigate whether the R to H mutation at the P1′ position of the COOH terminus of the epitope affects proteasome-mediated processing of the protein. Analysis of the generated products by tandem mass spectrometry and the kinetics of polypeptide processing in conjunction with CTL assays demonstrate that the R to H mutation alters proteasomal processing of the p53 protein by inhibiting proteolytic cleavage between residues 272 and 273. This prevents the release of the natural CTL epitope that spans flanking residues 264–272 as well as a putative precursor peptide. These results demonstrate that mutation of p53 not only leads to malignant transformation but may also, in some instances, affect immune surveillance and should be considered in the design of cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Self-citationGaczynska, M., Rock, K. L., Spies, T., & Goldberg, A. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9213 · Cited by 312
Cited by
DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
Antigen processing by the proteasome
Kloetzel, P.-M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35056572 · Cited by 637
Self-citationCancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
Stanislawski, T., Voss, R.-H., Lotz, C., Sadovnikova, E., Willemsen, R. A., Kuball, J., Ruppert, T., Bolhuis, R. L. H., Melief, C. J., Huber, C., et al. (2001) · Nature Immunology · doi:10.1038/ni1001-962 · Cited by 362
Self-citationProtein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
Prediction of proteasome cleavage motifs by neural networks
Keşmir, C., Nussbaum, A. K., Schild, H., Detours, V., & Brunak, S. (2002) · Protein Engineering, Design and Selection · doi:10.1093/protein/15.4.287 · Cited by 282
The proteasome activator 11 S REG (PA28) and Class I antigen presentation
RECHSTEINER, M., REALINI, C., & USTRELL, V. (2000) · Biochemical Journal · doi:10.1042/bj3450001 · Cited by 265
Strehl, B., Seifert, U., Krüger, E., Heink, S., Kuckelkorn, U., & Kloetzel, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00308.x · Cited by 234
Self-citationDahlmann, B., Ruppert, T., Kuehn, L., Merforth, S., & Kloetzel, P.-M. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4185 · Cited by 192
Self-citationStrategies for immunotherapy of cancer
Melief, C. J. M., Toes, R. M., Medema, J. P., Van Der Burg, S. H., Ossendorp, F., & Offringa, R. (2000) · Advances in Immunology · doi:10.1016/s0065-2776(00)75006-1 · Cited by 165
Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.484801 · Cited by 126
“However, peptide-based approaches assume knowledge of precise HLA types and the peptides present on particular tumors, leading to several limitations [21,22], such as technical difficulties with generating custom mutant-specific peptides and clinical trial designs that adequately assess this approach.”
BackgroundDevelopment of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Li, D., Bentley, C., Anderson, A., Wiblin, S., Cleary, K. L. S., Koustoulidou, S., Hassanali, T., Yates, J., Greig, J., Nordkamp, M. O., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3247 · Cited by 38
“19 type p53 peptide-MHC class I complexes than normal cells(25,31,32).”
BackgroundResult
Metadata
- Authors
- Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Häussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P.-M., & Sherman, L. A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-09-21
- Volume
- 188
- Issue
- 6
- Pages
- 1017-1028
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2116595225
- Cited by
- 117
- References
- 7
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.